Variant: rs5010528 

    present in Gene: HLA-B;HLA-C
    present in Chromosome: 6
    Position on Chromosome: 31273255
    Alleles of this Variant: A/G

rs5010528 in HLA-B;HLA-C gene and ACQUIRED IMMUNODEFICIENCY SYNDROME, PROGRESSION TO PMID 21051598 2010 The major genetic determinants of HIV-1 control affect HLA class I peptide presentation.

rs5010528 in HLA-B;HLA-C gene and AIDS, PROGRESSION TO PMID 21051598 2010 The major genetic determinants of HIV-1 control affect HLA class I peptide presentation.

rs5010528 in HLA-B;HLA-C gene and HIV Infections PMID 28062682 2017 Genome-wide association study of nevirapine hypersensitivity in a sub-Saharan African HIV-infected population.

rs5010528 in HLA-B;HLA-C gene and HIV-1, RESISTANCE TO PMID 21051598 2010 The major genetic determinants of HIV-1 control affect HLA class I peptide presentation.

rs5010528 in HLA-B;HLA-C gene and HUMAN IMMUNODEFICIENCY VIRUS TYPE 1, SUSCEPTIBILITY TO PMID 21051598 2010 The major genetic determinants of HIV-1 control affect HLA class I peptide presentation.

rs5010528 in HLA-B;HLA-C gene and Stevens-Johnson Syndrome PMID 28062682 2017 Genome-wide association study of nevirapine hypersensitivity in a sub-Saharan African HIV-infected population.

rs5010528 in HLA-B;HLA-C gene and Toxic Epidermal Necrolysis PMID 28062682 2017 The most promising signal was seen in SJS/TEN, where rs5010528 ( HLA-C locus) approached genome-wide significance ( P  <   8.5 × 10 -8 ) and was below HLA -wide significance ( P  <   2.5 × 10 -4 ) in the meta-analysis of discovery and replication cohorts [OR 4.84 (95% CI 2.71-8.61)]. rs5010528 is a strong proxy for HLA-C*04:01 carriage: in silico docking showed that two residues (33 and 123) in the B pocket were the most likely nevirapine interactors.